 CONSHOHOCKEN, Pa., Jan. 30, 2022 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ: MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022. 